Agios Pharmaceuticals, Inc. (LON:0HB0)

London · Delayed Price · Currency is GBP · Price in USD

27.76

-0.81 (-2.84%)

At close: Mar 19, 2026

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Development and Commercialization of Therapies for Patients with Rare Diseases	54.03M	36.50M	26.82M	14.24M				94.39M
Development and Commercialization of Therapies for Patients with Rare Diseases Growth	48.03%	36.07%	88.36%	-				119.45%
Total	54.03M	36.50M	26.82M	14.24M				94.39M
Total Growth	48.03%	36.07%	88.36%	-				119.45%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	54.03M	36.50M	26.82M	14.24M				94.39M
United States Growth	48.03%	36.07%	88.36%	-				119.45%
Total	54.03M	36.50M	26.82M	14.24M				94.39M
Total Growth	48.03%	36.07%	88.36%	-				119.45%

Source: S&P Global Market Intelligence.